The UK commercial reference for research-grade Semaglutide (NN9535) — the established GLP-1 receptor agonist peptide used extensively in laboratory research. ≥99% HPLC-UV release, batch-specific COA and UK cold-chain dispatch.
The established single-receptor GLP-1 reference peptide of the incretin class — supplied as a lyophilised 15 mg vial at ≥99% HPLC-UV with a batch-specific COA for in-vitro laboratory research only.
Semaglutide is a synthetic peptide analogue of the endogenous incretin hormone GLP-1. Discovered and developed under the Novo Nordisk code NN9535, it was engineered for extended plasma half-life via fatty-acid acylation and albumin binding, enabling once-weekly research dosing regimens in the primary literature.
Within the GLP-1 receptor agonist class, semaglutide sits alongside earlier analogues such as liraglutide as one of the most extensively studied single-receptor tool compounds — the reference peptide against which newer dual (tirzepatide) and triple (retatrutide) agonists are benchmarked.
The STEP and SUSTAIN Phase 3 programmes generated the deepest peer-reviewed evidence base for any GLP-1 receptor agonist to date. That published depth makes semaglutide the standard single-receptor comparator in in-vitro receptor-selectivity work, incretin-class benchmarking, and mechanism-of-action studies that need a well-characterised reference peptide.
Semaglutide is not tirzepatide and it is not retatrutide. It engages the GLP-1 receptor alone, without the GIP or glucagon receptor activity of the dual and triple agonists — that receptor selectivity is precisely why it remains the class baseline.
Semaglutide is the international non-proprietary name (INN) for the peptide originally developed by Novo Nordisk under the code NN9535. Under its licensed pharmaceutical brands the same molecule is sold as Ozempic (weekly injectable, type-2 diabetes), Wegovy (weekly injectable, weight management) and Rybelsus (daily oral, type-2 diabetes). Those are prescription medicines regulated by national medicines authorities.
BuyRetaUK does not supply Ozempic, Wegovy or Rybelsus. We supply research-grade semaglutide as a laboratory chemical for in-vitro use only. Nothing on this site is medical advice, a prescription, or an offer to sell a medicinal product.
Every vial ships with a batch-specific COA · UK dispatch
Every batch is independently released against a ≥99% HPLC-UV specification with mass-spec identity.
Cross-reference the batch number on your vial against the COA in the verification library.
Picked, packed and shipped under cold-chain protocols from our UK facility.
The established GLP-1 baseline — ideal for receptor-selectivity and class-benchmarking work.
Supplied strictly for laboratory research. Not a medicine — not Ozempic, Wegovy or Rybelsus.
Volumes for any concentration are handled by our reconstitution calculator.
| Research scenario | Recommended | Rationale |
|---|---|---|
| Single GLP-1 receptor baseline research | Semaglutide | Long-acting single-receptor GLP-1 agonist — the class reference peptide. |
| Dual GLP-1 / GIP receptor research | Tirzepatide | Adds GIP receptor activity on top of GLP-1 — the dual-incretin comparator. |
| Triple GLP-1 / GIP / Glucagon research | Retatrutide | Adds glucagon receptor activation on top of dual GLP-1/GIP — the triple-agonist step up. |
| Reconstitution / dilution | Bacteriostatic Water | Standard diluent for reconstituting lyophilised peptides. |
Reverse-phase HPLC quantifies purity as a percentage of total peak area. Release specification: ≥99%.
Learn more →Certificate of AnalysisEvery batch ships with a batch-specific COA reporting identity, purity and appearance.
Learn more →Laboratory QualityIndependent third-party analysis, temperature-controlled UK storage and full batch traceability.
Learn more →Batch VerificationCross-reference the batch number printed on your vial against our live COA library.
Learn more →Storage StandardsLyophilised at 2–8°C protected from light. Reconstituted stability ~30 days at 2–8°C.
Learn more →Cross-reference the batch number printed on your semaglutide vial against the certificate library. If you need help reading the analytical release data, see our Certificate of Analysis guide.
No. Ozempic, Wegovy and Rybelsus are Novo Nordisk's licensed prescription medicines that contain semaglutide. BuyRetaUK supplies research-grade semaglutide (NN9535) as a laboratory research material only. We do not sell, market or offer branded medicines.
Yes — BuyRetaUK supplies semaglutide as a research chemical for in-vitro laboratory use only. It is not offered or intended for human or veterinary administration.
Every batch is released at ≥99% by HPLC-UV, with identity confirmed by mass spectrometry, and ships with a batch-specific Certificate of Analysis published in our verification library.
One lyophilised strength: a 15 mg vial. The full pricing and add-to-cart flow lives on the product page.
Semaglutide activates one receptor (GLP-1). Tirzepatide activates two (GLP-1 and GIP). Retatrutide activates three (GLP-1, GIP and glucagon). Semaglutide is the established single-receptor reference compound of the class.
Peer-reviewed citations are added as each article is expanded. See our editorial standards for our sourcing and accuracy commitments.
The BuyRetaUK editorial team publishes laboratory-focused reference content on research peptides, analytical methods and Certificates of Analysis. All articles are written for in-vitro research contexts only.
View profile →Every editorial article is reviewed against our accuracy commitment and quality-assurance checklist before publication. Named reviewer profiles are added as our reviewer network expands.
View profile →Every article follows a documented editorial process — sourcing, scientific review, update cadence and correction policy — so researchers can rely on what we publish.
Read the full editorial standards →Educational first. Each step is optional — start wherever you are in your research.
Compound overview, receptor profile and research framing.
GLP-1 receptor engagement, Gαs / cAMP signalling and single-agonist pharmacology.
Published laboratory evidence, discovery lineage and research applications.
SUSTAIN, STEP and SELECT — published Phase 3 evidence summary.
HPLC-UV release, mass-spec identity and batch verification for Semaglutide.
Lyophilised handling, bacteriostatic water reconstitution and in-use stability for Semaglutide.
Selective GLP-1 receptor agonist vs dual GIP/GLP-1 agonist — balanced scientific comparison.
Research-grade semaglutide with batch-specific COA.
How retatrutide and semaglutide differ in receptor activity, compound class and laboratory research framing.
5 min read →Purity & Laboratory TestingThe quality standards BuyRetaUK applies to every batch — sourcing, analytical testing, storage and traceability.
5 min read →Storage & HandlingHow to store lyophilised research peptides and reconstitute them correctly for laboratory use.
4 min read →Product ComparisonsSide-by-side comparison of retatrutide and tirzepatide across receptor profile, research context and analytical considerations.
5 min read →Triple agonist vs single GLP-1 — class, mechanism and lab context.
View comparison →Side by sideSelective GLP-1 agonist vs dual GIP/GLP-1 agonist — receptor pharmacology and evidence comparison.
View comparison →Multi-compoundAll GLP-1 / GIP / glucagon research compounds in one place.
View comparison →Every batch of Semaglutide ships with a third-party HPLC and mass-spec Certificate of Analysis. Browse the live COA library to verify your lot.
Single-receptor GLP-1 vs triple incretin agonist — the canonical side-by-side.
View comparison →CatalogueSemaglutide catalogueThe stocked semaglutide vial with live pricing and add-to-cart.
Browse catalogue →VerificationCertificate libraryCross-reference your batch number against the public COA library.
Open library →https://buyretauk.com/semaglutide-uk
